Cancer Research Audrey Hepburn  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 28, 186-191, February 1, 1968]
© 1968 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bryan, G. T.
Right arrow Articles by Morris, C. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bryan, G. T.
Right arrow Articles by Morris, C. R.

Distribution of 14C-labeled 8-Methyl Ether of Xanthurenic Acid in the Mouse following Bladder Luminal, Subcutaneous, and Intraperitoneal Administration under Carcinogenic Conditions1

George T. Bryan and Carl R. Morris

The Division of Clinical Oncology, University of Wisconsin Medical School, Madison, Wisconsin

The distribution of 14C-labeled 8-methyl ether of xanthurenic acid (XAE), a human urinary metabolite of the amino acid tryptophan and a urinary bladder carcinogen for the mouse, was studied in mice. Four methods of administration were employed—surgical insertion into the bladder of a cholesterol pellet containing XAE, i.p. injection of XAE, direct instillation into the bladder lumen (i.u.), and s.c. injection into mice with (Group 1) and without (Group 2) cholesterol pellets in their bladders. Following surgical implantation of a pellet containing XAE, in 1–24 hr, 4–41% of the XAE was eluted from the pellets. Most of the 14C was retained in several tissues or was present in the gastrointestinal contents and feces. The urinary bladder retained much greater quantities of 14C than did other tissues. When an aqueous solution of XAE was placed i.u. into the mouse bladder, in 24 hr, nearly all disappeared from the bladder lumen. These data indicated that the bladder was permeable to XAE, and had ample opportunity for intimate contact with this compound during the acute period of exposure during the process of carcinogenesis.

Following s.c. administration of XAE to mice of Groups 1 and 2, in 24 hr, more than 95% of 14C was present in the urine, intestinal contents, feces, and CO2. The bladder specific activity in both groups was comparable. Thus differences in bladder carcinoma incidence observed previously for mice, similar to those in Groups 1 and 2, appeared unrelated to the quantity of XAE absorbed by the bladder following s.c. injection.

1 Supported in part by Grant No. CA-10017 from the National Cancer Institute, USPHS, and by Grants Nos. E-115 and E-116H from the American Cancer Society. Presented in part at the Ninth International Cancer Congress, Tokyo, Japan, October, 1966 (Abstracts, IX International Cancer Congress, 146, 1966).

Received 6/26/67. Accepted 10/18/67.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1968 by the American Association for Cancer Research.